Journal
STEM CELL RESEARCH
Volume 37, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.scr.2019.101434
Keywords
Human induced pluripotent stem cell; Trilineage differentiation; Ectoderm marker; NESTIN; PAX6
Funding
- National Institutes of Health Pharmacogenomics Research Network (PGRN) [P50 GM115318]
- National Institutes of Health NIGMS [R24 GM119977]
Ask authors/readers for more resources
Patient-derived induced pluripotent stem cells (iPSCs) have become a promising resource for exploring genetics of complex diseases, discovering new drugs, and advancing regenerative medicine. Increasingly, laboratories are creating their own banks of iPSCs derived from diverse donors. However, there are not yet standardized guidelines for qualifying these cell lines, i.e., distinguishing between bona fide human iPSCs, somatic cells, and imperfectly reprogrammed cells. Here, we report the establishment of a panel of 30 iPSCs from CD34(+) peripheral blood mononuclear cells, of which 10 were further differentiated in vitro into all three germ layers. We characterized these different cell types with commonly used pluripotent and lineage specific markers, and showed that NES, TUBB3, and OTX2 cannot be reliably used as ectoderm differentiation markers. Our work highlights the importance of marker selection in iPSC authentication, and the need for the field to establish definitive standard assays.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available